CLAD

Palantir Partners with University of Colorado Anschutz Medical Campus to Establish the All of Us Research Program’s Center for Linkage and Acquisition of Data (CLAD)

Retrieved on: 
Thursday, January 11, 2024
Health Technology, COVID-19, Data Management, Other Health, Technology, University, Education, Professional Services, Clinical Trials, Biotechnology, Science, Software, Other Science, Data Analytics, Research, Health, Mortality, Privacy, Principal, Health equity, CLAD, Partnership, Federal, Data collection, Government, Public health, Disease, PLTR, NIH, Human services, National Institutes of Health, Data science, Bangladesh Technical Education Board, EHR

Palantir Technologies Inc. (NYSE: PLTR) today announced its partnership with the University of Colorado Anschutz Medical Campus to establish the Center for Linkage and Acquisition of Data (CLAD) as part of the National Institutes of Health’s (NIH) All of Us Research Program.

Key Points: 
  • Palantir Technologies Inc. (NYSE: PLTR) today announced its partnership with the University of Colorado Anschutz Medical Campus to establish the Center for Linkage and Acquisition of Data (CLAD) as part of the National Institutes of Health’s (NIH) All of Us Research Program.
  • All of Us is a historic research effort to drive new scientific discoveries and advance precision medicine and research.
  • The University of Colorado Anschutz Medical Campus, Palantir and other partners will work with All of Us to configure a secure platform for processing new data streams.
  • The University of Colorado Anschutz Medical Campus, Palantir, and its partners were selected following an extensive and competitive process.

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Retrieved on: 
Tuesday, December 19, 2023
Patient, Immune system, EAP, Mortality, Disease, Lung transplantation, IPA, CLAD, Infection, Safety, Diagnosis, Phase II, History, TFF, Pharmaceutical industry

“Today is truly a remarkable moment in the history of TFF Pharmaceuticals, as these initial clinical data clearly demonstrate the efficacy and favorable safety and tolerability of TFF VORI and TFF TAC in two rare disease indications with high unmet medical need.

Key Points: 
  • “Today is truly a remarkable moment in the history of TFF Pharmaceuticals, as these initial clinical data clearly demonstrate the efficacy and favorable safety and tolerability of TFF VORI and TFF TAC in two rare disease indications with high unmet medical need.
  • “Based on these highly encouraging efficacy and safety data, we have made the decision to accelerate the development of TFF VORI and TFF TAC into registration-enabling studies, given the unequivocally positive results from these initial data.
  • Looking ahead, we expect to present additional clinical data in the first quarter of 2024 to further support the advancement of TFF VORI and TFF TAC into registration-enabling studies.”
    “These initial data provide compelling evidence that both TFF VORI and TFF TAC have game-changing potential in the treatment of their respective rare disease indication, IPA and prevention of rejection after lung transplantation,” said Zamaneh Mikhak, M.D., Chief Medical Officer of TFF Pharmaceuticals.
  • Additionally, the patients maintained their kidney function and chose to remain on TFF TAC long term.”
    The ongoing Phase 2 trial of TFF VORI is an open-label, randomized (3:1) study evaluating treatment with TFF VORI versus oral voriconazole over a 13-week period in patients with IPA.

Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Retrieved on: 
Wednesday, August 16, 2023
Science, Cardiology, Other Science, Research, Surgery, Health, Genetics, Clinical Trials, DNA, Medicaid, CMS, CLAD, Lung transplantation, Nucleic acid thermodynamics, Survival, Houston Methodist Hospital, Medicare, Medicine, Patient, Centers for Medicare & Medicaid Services, Mortality, Nursing care plan, AR, NTRA, Biopsy, Dentistry, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).
  • The MolDX technology assessment program has determined that Prospera Lung will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients.
  • This blinded, prospective study analyzed Prospera Lung in connection with various complications from lung transplantation, including AR, CLAD and allograft infection.
  • “Medicare’s decision enables broad access to the Prospera Lung test and represents a significant win for lung transplant patients and the field of transplant monitoring,” said Bernie Tobin, general manager of organ health at Natera.

Mallinckrodt Announces 2022 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award

Retrieved on: 
Wednesday, November 16, 2022
Quality of life, Lung transplantation, Newcastle University, SEC, Neurology, MNK, Mortality, Survival, Immunotherapy, Ajman Specialty General Hospital, CLAD, Knowledge, Nephrology, Analgesic, Medicine, Company, Immunomodulation, Rheumatology, Time, ECP, NYSE, Institute, U.S. Securities and Exchange Commission, Death, Patient, Risk, Ophthalmology, Hospital, Disability, Virulent Newcastle disease, Autoimmunity, Science, Longevity, Treatment, Biomarker, Newcastle upon Tyne Hospitals NHS Foundation Trust, Medical device, Dentistry, Pharmaceutical industry, Mallinckrodt, Transplant

DUBLIN, Nov. 16, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. Andrew Fisher, the project's principal investigator won this year's award for a project to help address significa­­nt unmet medical need by evaluating responses to extracorporeal photopheresis therapy (ECP) in chronic lung allograft dysfunction (CLAD).

Key Points: 
  • DUBLIN, Nov. 16, 2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award.
  • Andrew Fisher, the project's principal investigator won this year's award for a project to help address significant unmet medical need by evaluating responses to extracorporeal photopheresis therapy (ECP) in chronic lung allograft dysfunction (CLAD).
  • The award, now in its fifth year, is part of Mallinckrodt's ongoing commitment to the science of immunomodulation through ECP across therapeutic applications.
  • "As a pioneer in ECP immunomodulation, Mallinckrodt is proud to support those who continue to investigate this exciting field of medicine.

Zambon to Attend the CHEST Annual Meeting 2022

Retrieved on: 
Friday, October 14, 2022
T cell, Amyotrophic lateral sclerosis, Autoimmune disease, Respiratory tract, Lung, BOS, Liposome, Inhalation, European Medicines Agency, Cleveland Clinic, American College, Urinary tract infection, Degenerative disease, Regulation of tobacco by the U.S. Food and Drug Administration, American College of Chest Physicians, Phenotype, Parkinson's disease, Pain management, ALS, Respiratory system, Inflammation, Cystic fibrosis, Company, CE, Riluzole, CMO, FDA, Pathology, Disease, Diagnosis, Critical Care Medicine (journal), CME, Stanford University, Death, CLAD, Life, MOC, Education, Patient, Orphan drug, Food, Immune system, Medicare, MD, Health, Convention, Safety, Fast Track, Obliterative bronchiolitis, Bronchiole, Pharmaceutical industry, Dentistry, Medical device, Zambon

In addition, Zambon is sponsoring a learning theater focused on the current understanding of BOS, including its clinical features, diagnosis, progression and treatment options.

Key Points: 
  • In addition, Zambon is sponsoring a learning theater focused on the current understanding of BOS, including its clinical features, diagnosis, progression and treatment options.
  • This event is not part of the official CHEST Annual Meeting 2022 conference sessions.
  • This event is not endorsed by CHEST and does not reflect the views or opinions of CHEST.
  • In Europe, Zambon also plans to market and distribute, upon regulatory approval, an innovative oral formulation of riluzole for patients suffering with Amyotrophic Lateral Sclerosis (ALS).

CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction

Retrieved on: 
Wednesday, May 18, 2022
Physician, Research and development, International Society, DNA, Lung transplantation, Disease, Survival, Nasdaq, Doctor of Philosophy, Transplant, Heart transplantation, Patient, Lung, CLAD, CE, Mortality, Caregiver, Hope, Award, SAN, Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology, Nucleic acid thermodynamics, Center, Biomarker, Heart, International Society for Heart and Lung Transplantation, Heart failure, Precision medicine, GEP, SEC, Laboratory, Northwestern Memorial Hospital, CEO, Annual report, GLOBE, Dentistry, Research, Medicine, Northwestern University

"As a leader committed to advancing the field of transplantation, CareDx is proud to sponsor the ISHLT Innovation Challenge Award.

Key Points: 
  • "As a leader committed to advancing the field of transplantation, CareDx is proud to sponsor the ISHLT Innovation Challenge Award.
  • This award will help advance the important research that Dr. Sez-Gimnez is undertaking to address one of the most pressing issues facing lung transplant patients, the development of irreversible chronic lung allograft dysfunction and one of the leading causes of mortality," said Reg Seeto, CEO and President of CareDx.
  • The selected project aims to focus on the correlation of dd-cfDNA and chronic lung allograft dysfunction (CLAD), which is the main complication hampering survival in patients at Dr. Sez-Gimnez's clinic.
  • This press release includes forward-looking statements related to CareDx, Inc., including statements regarding Dr. Sez-Gimnez's winning of CareDx's sponsored ISHLT Innovation Challenge Award (the "Award") and her research to use AlloSeq cfDNA to monitor the treatment of chronic lung allograft dysfunction (the "Research").

ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION

Retrieved on: 
Friday, May 6, 2022
Forward-looking statement, TPH, BOS, Constriction, VideoRay UROVs, Death, NYSE, Respiratory tract, CA, ATS, Poster, PAH, Patient, Lung transplantation, Pulmonary hypertension, Survival, Tryptophan hydroxylase, FDA, CLAD, Degenerative disease, Serotonin, Hepatic artery proper, Heart, LinkedIn, Disease, Hypertensive emergency, Vasoconstriction, Ambrisentan, Pathology, Vasodilation, Vascular remodelling in the embryo, Multimedia, Pharmaceutical industry

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries.

Key Points: 
  • Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries.
  • These changes lead to high pulmonary arterial pressure, right heart strain, and ultimately, right heart failure and death.
  • Altavant is currently testing this mechanism of action in ELEVATE 2, a proof-of-concept Phase 2 study of rodatristat ethyl in patients with PAH.
  • Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor in Phase 2 development for patients with pulmonary arterial hypertension.

ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530

Retrieved on: 
Monday, May 2, 2022
Lazarus, Optimism, Forward-looking statement, TPH, BOS, IL-6, VideoRay UROVs, SVP, Development, International Society for Heart and Lung Transplantation, NYSE, Respiratory tract, PAH, APG system, Patient, Fibrosis, Lung transplantation, Lung, Tryptophan hydroxylase, FDA, CLAD, Degenerative disease, Serotonin, Bronchiole, LinkedIn, Disease, Hypertensive emergency, International Society, Vascular remodelling in the embryo, Multimedia, Pharmaceutical industry, Vaccine, Research

Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung.

Key Points: 
  • Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung.
  • , Altavant's Chief Medical Officer added, "Following lung transplant, inappropriate activation of the innate immune system has been shown to drive transplant rejection.
  • ALTA-2530 is currently in preclinical development at Altavant for the treatment of BOS and chemical lung injuries.
  • Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases.

Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022

Retrieved on: 
Tuesday, April 26, 2022
ALS, Amyotrophic lateral sclerosis, Pain management, Transplant, Time, Degenerative disease, Parkinson's disease, Respiratory tract, Program, Patient, Riluzole, Lung, International Society for Heart and Lung Transplantation, CLAD, Lung transplantation, Obliterative bronchiolitis, Company, Respiratory system, Disease, International Society, Survival, Mark (given name), CMO, Scar, Arrest, Urinary tract infection, Health, Cystic fibrosis, Pharmaceutical industry, Dentistry, Zambon, Death, BOS

The first analysis to be presented, titled Survival After Lung Transplantation in Europe - Chronic Lung Allograft Dysfunction (CLAD) as Major Cause of Death, examines CLAD's impact on patient survival rates following lung transplantation, including CLAD phenotype Bronchiolitis Obliterans Syndrome (BOS).

Key Points: 
  • The first analysis to be presented, titled Survival After Lung Transplantation in Europe - Chronic Lung Allograft Dysfunction (CLAD) as Major Cause of Death, examines CLAD's impact on patient survival rates following lung transplantation, including CLAD phenotype Bronchiolitis Obliterans Syndrome (BOS).
  • "At Zambon, we recognize the significant impact that severe respiratory diseases can have on patients, as well as the barriers to long-term survival following lung transplantation.
  • Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction (CLAD) after lung transplantation (also referred to as chronic rejection).
  • In Europe, Zambon also plans to market and distribute, upon regulatory approval, an innovative oral formulation of riluzole for patients suffering with Amyotrophic Lateral Sclerosis (ALS).

Natera Adds to Organ Health Medical Affairs Leadership Team

Retrieved on: 
Wednesday, April 6, 2022
Form 10-K, CLIA, Lung transplantation, NASDAQ, DNA, Leadership, Harefield Hospital, American Society of Transplantation, Chicago (franchise), Frailty, Growth, United Kingdom, Multimedia, UK, NTRA, Cedars-Sinai Medical Center, National Heart, Lung, and Blood Institute, Clinical Laboratory, Royal Brompton Hospital, Research, SEC, Risk, CLAD, Medicine, Health, Laboratory, Ronald, Critical care, International Society, International Society for Heart and Lung Transplantation, Society, Genetic testing, David Geffen School of Medicine at UCLA, Kidney transplantation, Algorithm, ISO, Imperial College London, University, Heart transplantation, UCLA, Stanford University, Lung cancer, Antibody, Medical device, Dentistry, Natera, Northwestern University

AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the hiring of Sangeeta Bhorade, M.D., as vice president of organ health medical affairs. Dr. Bhorade joins Natera as the latest addition amongst other recent notable medical leadership hires, including Michael Olymbios, M.D., medical director of heart transplantation, and David Ross, M.D., medical director of lung transplantation.

Key Points: 
  • AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the hiring of Sangeeta Bhorade, M.D., as vice president of organ health medical affairs.
  • Dr. Bhorade joins Natera as the latest addition amongst other recent notable medical leadership hires, including Michael Olymbios, M.D., medical director of heart transplantation, and David Ross, M.D., medical director of lung transplantation.
  • Natera's medical leadership for organ health now brings more than 110 years of combined experience spanning multiple organ health specialties - including Phil Gauthier, M.D., lead senior medical director of organ health and Hoss Tabriziani, M.D., senior medical director of kidney transplantation, who have been with the company since 2019 and 2020, respectively.
  • Naterais a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health.